ReviewNature reviews. Neurology2025
The global and regional burden of diabetic peripheral neuropathy.
Review in Nature reviews. Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy.Diabetes, obesity & metabolism · 2026Pooled it
- Virtual Reality-Based Rehabilitation to Improve Mobility and Prevent Falls in Older People With Diabetic Peripheral Neuropathy: Evidence Synthesis and Development of a Geriatric-Specific Framework.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2026Pooled it
- Oral, intravenous, or sequential alpha-lipoic acid for diabetic peripheral neuropathy? A Bayesian network meta-analysis of randomized controlled trials.Frontiers in neurology · 2026Pooled it
- Pregabalin and duloxetine combination for painful diabetic neuropathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Efficacy and safety of Buyang Huanwu Decoction combined with α-lipoic acid for diabetic peripheral neuropathy: a systematic review with in-depth heterogeneity deconstruction and methodological appraisal.Frontiers in endocrinology · 2026Pooled it
- Machine learning in the prediction of diabetic peripheral neuropathy: a systematic review.BMC medical informatics and decision making · 2025Pooled it
- Traditional Chinese medicine for diabetic peripheral neuropathy: a network meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Experiences and needs of individuals living with diabetic peripheral neuropathy: a qualitative systematic review and meta-synthesis.Frontiers in neurologyPooled it
- Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study).BMJ open diabetes research & care · 2026Trial
- Longitudinal assessment of metabolic and neurological decline in peripheral polyneuropathy over ten years.Future science OA · 2026Article
- A multimodal manual therapy, exercise, and psychological intervention for painful diabetic neuropathy: the NeuOst feasibility randomised controlled trial.Pain reports · 2026Article
- Modeling Diabetic Neuropathy: Injury Biomarkers for Early Detection Through Neuronal and Glial In Vitro Models.International journal of molecular sciences · 2026Review
- NONcNZO10/LtJ and TALLY-HO/JngJ Mice as Novel Models of Diabetic Peripheral Neuropathy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Diabetes and the Metabolic Syndrome as Drivers of Neurodegeneration: Convergent Mechanisms Linking Peripheral Neuropathy and Dementia.Annals of neurology · 2026Review
- Antidiabetic Treatment Intensity and Diabetic Peripheral Neuropathy in a County-Level Metabolic Management Center: A Real-World Cross-Sectional Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Semaphorins and Their Role in Neuropathic Pain.Life (Basel, Switzerland) · 2026Review
- Therapeutic potential of spexin in diabetic neuropathy: Insights from in vitro and in vivo models.Experimental physiology · 2026Article
- Diabetic Peripheral Neuropathy May Be an Independent Risk Marker for Dementia and Cerebrovascular Disease.Diabetes, obesity & metabolism · 2026Article
- Identification of potential mechanisms of quercetin in diabetic peripheral neuropathy through integrated network pharmacology and experimental validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ultrasound-Activated Piezoelectric Neuroimmune Hydrogel Orchestrates Neurogenesis-Macrophage Crosstalk in Diabetic Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diabetic peripheral neuropathy (DPN) is length-dependent peripheral nerve damage arising as a complication of type 1 or type 2 diabetes in up to 50% of patients. DPN poses a substantial burden on patients, who can experience impaired gait and loss of balance, predisposing them to falls and fractures, and neuropathic pain, which is frequently difficult to treat and reduces quality of life. Advanced DPN can lead to diabetic foot ulcers and non-healing wounds that often necessitate lower-limb amputation. From a socioeconomic perspective, DPN increases both direct health-care costs and indirect costs from loss of productivity owing to neuropathy-related disability. In this Review, we highlight the importance of understanding country-specific and region-specific variations in DPN prevalence to inform public health policy and allocate resources appropriately. We also explore how identification of DPN risk factors can guide treatment and prevention strategies and aid the development of health-care infrastructure for populations at risk. We review evidence that metabolic factors beyond hyperglycaemia contribute to DPN development, necessitating a shift from pure glycaemic control to multi-targeted metabolic control, including weight loss and improvements in lipid profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.